Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;13(3):141-154.
doi: 10.1038/nrrheum.2016.217. Epub 2017 Feb 9.

Ectopic lymphoid neogenesis in rheumatic autoimmune diseases

Affiliations
Free article
Review

Ectopic lymphoid neogenesis in rheumatic autoimmune diseases

Michele Bombardieri et al. Nat Rev Rheumatol. 2017 Mar.
Free article

Abstract

Ectopic lymphoid neogenesis often occurs in the target tissues of patients with chronic rheumatic autoimmune diseases such as rheumatoid arthritis, Sjögren syndrome and other connective tissue disorders, including systemic lupus erythematosus and myositis. However, the mechanisms of ectopic lymphoid-like structure (ELS) formation and function are not entirely understood. For example, it is unclear whether ELSs indicate distinct disease phenotypes or whether they are evolutionary manifestations of chronic inflammation. Also unclear is why ELSs form in some patients but not in others. Nonetheless, ELSs frequently display functional features of ectopic germinal centres and can actively contribute to the maintenance of autoimmunity through the production of disease-specific autoantibodies; furthermore, they seem to influence disease severity and response to both synthetic and biologic DMARDs. In this Review, we discuss current knowledge and gaps in understanding of ELS formation and function including their prevalence in the above rheumatic autoimmune diseases; the mechanisms underlying their formation, maintenance and function, including positive and negative regulatory pathways; their functional relevance in the perpetuation of autoimmunity; their relationship with disease phenotypes, clinical outcomes and response to treatment; and the potential for specific targeting of ELSs through novel therapeutic modalities.

PubMed Disclaimer

References

    1. Rheumatology (Oxford). 2014 Oct;53(10):1886-95 - PubMed
    1. J Clin Invest. 2013 Feb;123(2):712-26 - PubMed
    1. J Exp Med. 2005 Apr 18;201(8):1229-41 - PubMed
    1. Nat Immunol. 2007 Nov;8(11):1255-65 - PubMed
    1. Immunol Rev. 2010 Jan;233(1):267-85 - PubMed

MeSH terms

LinkOut - more resources